Search research articles
Contact Us
Filters
Showing results (1-10 of 144) with videos related to
Page
of 15
Sort By:
Frontiers in Bioscience : a Journal and Virtual Library
|
September 9, 2005
Viral vectors for cancer immunotherapy
Richard Harrop, Miles W Carroll
Vaccine
|
March 26, 2013
Recombinant MVA vaccines: dispelling the myths
Matthew G Cottingham, Miles W Carroll
Advanced Drug Delivery Reviews
|
October 13, 2006
Recombinant viral vectors: cancer vaccines
Richard Harrop, Justin John, Miles W Carroll
Ebiomedicine
|
January 3, 2026
Current knowledge on the host-pathogen interactions of henipaviruses and novel platforms to enable further characterisation
Jakub Hantabal, F Javier Salguero, Miles W Carroll
Vaccine
|
July 9, 2017
Development of vaccines against Crimean-Congo haemorrhagic fever virus
Stuart D Dowall, Miles W Carroll, Roger Hewson
Frontiers in Immunology
|
March 8, 2021
Ebolavirus: Comparison of Survivor Immunology and Animal Models in the Search for a Correlate of Protection
Stephanie Longet, Jack Mellors, Miles W Carroll, et al.
Frontiers in Immunology
|
April 17, 2023
Pre-clinical models to define correlates of protection for SARS-CoV-2
Caolann Brady, Tom Tipton, Stephanie Longet, et al.
Methods in Molecular Biology (Clifton, N.J.)
|
April 29, 2004
Monitoring of human immunological responses to vaccinia virus
Richard Harrop, Matthew G Ryan, Hana Golding, et al.
Immunology
|
April 25, 2006
Identification of a major histocompatibility complex class I-restricted T-cell epitope in the tumour-associated antigen, 5T4
Irina Redchenko, Richard Harrop, Matthew G Ryan, et al.
Pathogens (Basel, Switzerland)
|
September 28, 2021
Filovirus Neutralising Antibodies: Mechanisms of Action and Therapeutic Application
Alexander Hargreaves, Caolann Brady, Jack Mellors, et al.
Page
of 15
Search research articles
Search
Showing results (1-10 of 144) with videos related to
Sort By:
Page
of 15
Frontiers in Bioscience : a Journal and Virtual Library
|
September 9, 2005
Viral vectors for cancer immunotherapy
Richard Harrop, Miles W Carroll
Vaccine
|
March 26, 2013
Recombinant MVA vaccines: dispelling the myths
Matthew G Cottingham, Miles W Carroll
Advanced Drug Delivery Reviews
|
October 13, 2006
Recombinant viral vectors: cancer vaccines
Richard Harrop, Justin John, Miles W Carroll
Ebiomedicine
|
January 3, 2026
Current knowledge on the host-pathogen interactions of henipaviruses and novel platforms to enable further characterisation
Jakub Hantabal, F Javier Salguero, Miles W Carroll
Vaccine
|
July 9, 2017
Development of vaccines against Crimean-Congo haemorrhagic fever virus
Stuart D Dowall, Miles W Carroll, Roger Hewson
Frontiers in Immunology
|
March 8, 2021
Ebolavirus: Comparison of Survivor Immunology and Animal Models in the Search for a Correlate of Protection
Stephanie Longet, Jack Mellors, Miles W Carroll, et al.
Frontiers in Immunology
|
April 17, 2023
Pre-clinical models to define correlates of protection for SARS-CoV-2
Caolann Brady, Tom Tipton, Stephanie Longet, et al.
Methods in Molecular Biology (Clifton, N.J.)
|
April 29, 2004
Monitoring of human immunological responses to vaccinia virus
Richard Harrop, Matthew G Ryan, Hana Golding, et al.
Immunology
|
April 25, 2006
Identification of a major histocompatibility complex class I-restricted T-cell epitope in the tumour-associated antigen, 5T4
Irina Redchenko, Richard Harrop, Matthew G Ryan, et al.
Pathogens (Basel, Switzerland)
|
September 28, 2021
Filovirus Neutralising Antibodies: Mechanisms of Action and Therapeutic Application
Alexander Hargreaves, Caolann Brady, Jack Mellors, et al.
Page
of 15